50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#59

Leuprolide

Reproductive HealthLupronEligardLeuprorelinLeuprolide AcetateViadur

One of the most widely prescribed GnRH agonists globally, FDA-approved for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of assisted reproduction protocols.

Share:

Overview

Leuprolide (also known as leuprorelin) is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) that has become one of the most commercially successful and widely used peptide drugs in the world. Developed by Abbott Laboratories (now AbbVie) and first approved by the FDA in 1985, leuprolide incorporates a D-leucine substitution at position 6 and an ethylamide group at the C-terminus, making it approximately 15-100 times more potent than native GnRH.

Leuprolide's primary mechanism involves the initial stimulation of pituitary gonadotropin release (the flare effect), followed by profound and sustained suppression of the hypothalamic-pituitary-gonadal axis through receptor downregulation. When administered continuously, it reduces testosterone in men and estradiol in women to castrate/postmenopausal levels. This sustained hormone suppression forms the basis for its therapeutic applications across oncology, gynecology, and pediatric endocrinology.

In oncology, leuprolide is a cornerstone of androgen deprivation therapy (ADT) for advanced prostate cancer. It is often combined with an anti-androgen during the initial treatment period to mitigate the clinical effects of the testosterone flare. In gynecology, it is used to manage endometriosis pain, reduce uterine fibroids before surgery, and as part of controlled ovarian stimulation protocols in IVF. In pediatrics, it remains a first-line treatment for central precocious puberty.

Multiple formulations have been developed to maximize convenience and compliance, including monthly, 3-month, 4-month, and 6-month depot injections, as well as a 12-month subcutaneous implant (Viadur, now discontinued). The availability of extended-release formulations has been crucial for ensuring consistent hormone suppression in oncology patients.

Research Uses & Applications

  • Palliative treatment of advanced prostate cancer via androgen deprivation
  • Treatment of endometriosis-associated pain and lesion regression
  • Preoperative management of uterine fibroids to reduce size and vascularity
  • Treatment of central precocious puberty in children
  • Pituitary downregulation in controlled ovarian stimulation for IVF
  • Off-label use in gender-affirming care as a puberty blocker

Key Research Findings

  • Pivotal trials demonstrated leuprolide achieves testosterone suppression to <50 ng/dL in over 90% of prostate cancer patients, with sustained suppression throughout treatment.
  • Studies in endometriosis showed leuprolide depot significantly reduces pain scores and endometriotic implant size comparable to danazol with a more favorable side effect profile.
  • Long-term follow-up in central precocious puberty confirmed preservation of adult height potential with treatment, with mean height gain of approximately 5-7 cm compared to predicted untreated height.
  • Research comparing depot formulations showed bioequivalent suppression between monthly and 3-month preparations, supporting extended dosing intervals.
  • The addition of add-back therapy (low-dose norethindrone acetate) was shown to mitigate bone loss and vasomotor symptoms without compromising efficacy in endometriosis treatment.

Risks & Side Effects

  • Hot flashes, sweating, and vasomotor symptoms are very common due to sex hormone suppression.
  • Initial testosterone flare can worsen prostate cancer symptoms (bone pain, urinary obstruction) and may require anti-androgen coverage.
  • Long-term use leads to decreased bone mineral density and increased osteoporotic fracture risk.
  • Associated with metabolic changes including increased body fat, insulin resistance, and unfavorable lipid changes.
  • Mood changes, depression, and cognitive effects have been reported, particularly with prolonged therapy.

Administration

Available as intramuscular or subcutaneous depot injections in multiple formulations: monthly (7.5 mg), 3-month (22.5 mg), 4-month (30 mg), and 6-month (45 mg). For IVF, daily subcutaneous injections of 0.5-1 mg of the non-depot formulation are used. Dose and duration vary by indication. Concurrent anti-androgen therapy is often recommended during the first 2-4 weeks for prostate cancer patients.

Legal Status

FDA-approved prescription medication with multiple approved indications. Marketed as Lupron Depot, Eligard, and other brand names. Available by prescription only. One of the most commercially successful peptide drugs ever, with peak annual sales exceeding $2 billion. Not a controlled substance.

Frequently Asked Questions

What is Leuprolide?

One of the most widely prescribed GnRH agonists globally, FDA-approved for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of assisted reproduction protocols.

What are the main uses of Leuprolide?

The primary research applications of Leuprolide include: Palliative treatment of advanced prostate cancer via androgen deprivation; Treatment of endometriosis-associated pain and lesion regression; Preoperative management of uterine fibroids to reduce size and vascularity; Treatment of central precocious puberty in children; Pituitary downregulation in controlled ovarian stimulation for IVF; Off-label use in gender-affirming care as a puberty blocker.

What are the risks and side effects of Leuprolide?

Documented risks and side effects include: Hot flashes, sweating, and vasomotor symptoms are very common due to sex hormone suppression.; Initial testosterone flare can worsen prostate cancer symptoms (bone pain, urinary obstruction) and may require anti-androgen coverage.; Long-term use leads to decreased bone mineral density and increased osteoporotic fracture risk.; Associated with metabolic changes including increased body fat, insulin resistance, and unfavorable lipid changes.; Mood changes, depression, and cognitive effects have been reported, particularly with prolonged therapy.. Always consult a healthcare professional before considering any peptide.

Is Leuprolide legal?

FDA-approved prescription medication with multiple approved indications. Marketed as Lupron Depot, Eligard, and other brand names. Available by prescription only. One of the most commercially successful peptide drugs ever, with peak annual sales exceeding $2 billion. Not a controlled substance.

How is Leuprolide administered?

Available as intramuscular or subcutaneous depot injections in multiple formulations: monthly (7.5 mg), 3-month (22.5 mg), 4-month (30 mg), and 6-month (45 mg). For IVF, daily subcutaneous injections of 0.5-1 mg of the non-depot formulation are used. Dose and duration vary by indication. Concurrent anti-androgen therapy is often recommended during the first 2-4 weeks for prostate cancer patients.

Related Peptides

#23

Kisspeptin-10

Reproductive Health

#28

Oxytocin

Reproductive Health

#54

Gonadorelin

Reproductive Health

#55

Triptorelin

Reproductive Health

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #58 Deslorelin#60 Nafarelin →